Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder CarcinomaEmil Christensen, Lars Dyrskjøt, Thomas Reinert et al.|Journal of Clinical Oncology|2019Cited by 540
Genomic Alterations in Liquid Biopsies from Patients with Bladder CancerKarin Birkenkamp‐Demtröder, Lars Dyrskjøt, Iver Nordentoft et al.|European Urology|2016Cited by 236
Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysisAnn Taber, Lars Dyrskjøt, Emil Christensen et al.|Nature Communications|2020Cited by 216
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder CancerEmil Christensen, Lars Dyrskjøt, Karin Birkenkamp‐Demtröder et al.|European Urology|2017Cited by 197
Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy AnalysisKarin Birkenkamp‐Demtröder, Lars Dyrskjøt, Emil Christensen et al.|European Urology|2017Cited by 176